<DOC>
	<DOCNO>NCT02120638</DOCNO>
	<brief_summary>Multidrug resistant tuberculosis ( MDR-TB ) difficult treat raise great challenge TB control program . That pyrazinamide shorten course treatment facilitate bacilli clearance prove recently . In 2011 , WHO recommend use pyrazinamide throughout course treatment MDR-TB . However , pyrazinamide susceptibility test widely use clinic . And conventional test time-consuming unreliable . In contrast , detection pncA rpsA mutation molecular method provide rapid result pyrazinamide susceptibility . The purpose study evaluate efficacy introduce molecular test pyrazinamide susceptibility optimize MDR-TB treatment regimen .</brief_summary>
	<brief_title>Optimization MDR-TB Treatment Regimen Based Molecular Drug Susceptibility Results Pyrazinamide</brief_title>
	<detailed_description>This phase 3 , open label , prospective cohort study evaluate molecular test pyrazinamide susceptibility optimize MDR-TB treatment regimen . Approximately 100 participant give molecular detection pncA rpsA mutation divide pyrazinamide sensitive comparator group pyrazinamide resistant group base susceptibility result . For pyrazinamide sensitive group , regimen contain six month chemotherapy pyrazinamide , amikacin , levofloxacin , plus prothionamide , follow six month pyrazinamide , levofloxacin , clarithromycin , plus prothionamide . For pyrazinamide resistant group , regimen contain six month chemotherapy isoniazid , amikacin , levofloxacin , plus prothionamide , follow eighteen month isoniazid , levofloxacin , clarithromycin , plus prothionamide . The participant follow 24 month start treatment . The primary outcome sputum culture conversion adverse event . Safety evaluation perform routine lab test , blood glucose , hearing , vital sign , ECG , report adverse event , physical examination X-rays .</detailed_description>
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Disease Susceptibility</mesh_term>
	<mesh_term>Tuberculosis , Multidrug-Resistant</mesh_term>
	<mesh_term>Isoniazid</mesh_term>
	<mesh_term>Pyrazinamide</mesh_term>
	<mesh_term>Prothionamide</mesh_term>
	<mesh_term>Levofloxacin</mesh_term>
	<mesh_term>Ofloxacin</mesh_term>
	<mesh_term>Clarithromycin</mesh_term>
	<mesh_term>Amikacin</mesh_term>
	<criteria>Patients diagnose active tuberculosis Patients smear positive sputum culture positive tuberculosis History active tuberculosis le 3 year With less 2 time previous antituberculous therapy The patient voluntarily enter study willing sign consent form full knowledge risk , schedule , drug feature study . MDRTB define resistance follow two drug : Isoniazid Rifampicin . Extensively drugresistant ( XDRTB ) define resistance flouroquinolones one three secondline antituberculous injection ( capreomycin , kanamycin , amikacin ) The study enrol MDRTB subject exclude XDRTB subject . If MDRTB subject also resistant flouroquinolones capreomycin ( kanamycin , amikacin ) , subject include study preXDR TB patient . Known allergy intolerance drug study Liver damage ( Hepatic encephalopathy ; ascites ; prothrombin time prolong 2 second compare normal control ; blood bilirubin 3 time great upper limit normal range ) Platelets &lt; 150x109 / L , WBC &lt; 3x109 / L. Abnormal ECG ( Male patient prolong QT interval exceed 430ms , Female patient prolong QT interval exceed 450ms ) Serum creatinine 1.5 time high upper limit Fasting bloodglucose high 8.0 mmol/L Patients medication effect result drug study Karnofsky score &lt; 50 % ( see appendix ) Women pregnant breastfeeding HIV positive Participating clinical trial past three month Patients mental illness severe neurosis Patients poor compliance Any special circumstance research physician believe suitable study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Multidrug Resistant Tuberculosis</keyword>
	<keyword>Pyrazinamide</keyword>
</DOC>